Asthma control and clinical remission in severe eosinophilic asthma (SEA) after 2 years of benralizumab treatment: prospective real-world data from XALOC-2 - Amsterdam 2025

Remission/stability in airway diseases: how to achieve and what is next?

Chair(s): Guy Brusselle, Corrado Pelaia

Session type: Poster session

Asthma control and clinical remission in severe eosinophilic asthma (SEA) after 2 years of benralizumab treatment: prospective real-world data from XALOC-2

Marek Lommatzsch

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following 2 years of treatment with anti-IL-5/R therapies

Alessandra Vultaggio

Poster

Abstract

Clinical remission rates in severe asthma and its predictive factors in a real world setting from Argentina

Maria Eugenia Franchi

Poster

Abstract

Biologic therapy improves clinical outcomes in severe asthma with incomplete response to long term antibiotics

Peer Ameen Shah

Poster

Abstract

From disease improvement to disease stability in patients with COPD: IMPACT post hoc analysis

Dave Singh

Poster

Abstract

Observational analysis of biological remission in severe asthma: UK severe asthma registry (UKSAR)

P Jane Mcdowell

Poster

Abstract

Remission outcomes in difficult-to-treat allergic asthma with bacterial lysate 0M-85 therapy: A RWE study

Antonios Christopoulos

Poster

Abstract

Disease stability in COPD with umeclidinium/vilanterol (UMEC/VI) compared to tiotropium (TIO), umeclidinium, and salmeterol (SAL): post hoc analyses of ZEP and EMAX studies

Lowie Vanfleteren

Poster

Abstract

Five years of anti-IL 5 for severe asthma: promising long-term efficacy, but sustained remission is rare

Kjell E J Håkansson

Poster

Abstract

Asthma control and clinical remission in severe eosinophilic asthma (SEA) after 2 years of benralizumab treatment: prospective real-world data from XALOC-2

Marek Lommatzsch

Poster

Abstract

Clinical Practice aplicability of the clinical remission concept in patients with seve eosinophilic bronchial asthma treated with anti- Interleukin 5 antibodies

Ana Isabel Sogo Sagardia

Poster

Abstract

Stringent American (ATS/ACAAI/AAAAI) endorsed 6-component definition of asthma remission is not achievable in a real-world benralizumab cohort

Jennifer Logan

Poster

Abstract

Dupilumab impact on clinical asthma remission by baseline inhaled corticosteroid dose

Nicola Hanania

Poster

Abstract

The 3TR-Asthma Biologic Cohort (ABC) study: an umbrella platform design to understand mechanisms of remission in severe asthma patients on biologics.

Stefania Principe

Poster

Abstract

Enhancing Clinical Remission and Reducing Health Care Utilization in Severe Eosinophilic Asthma: Real-World Benefits of Benralizumab in Belgium

Leen Janssen

Poster

Abstract

Inhaled Corticosteroid Reduction Effects on Asthma Outcomes after Three Years of Benralizumab Treatment in Severe Asthma Patients

Marta Arteaga Romero

Poster

Abstract

Clinical remission in severe asthma: comparison between different definitions of lung function stability

Cecilia Rivero

Poster

Abstract

Clinical profile of severe asthma (SA) patients Mexican vs Global data and evolution once in the international severe asthma registry (ISAR)

Désirée Larenas-linnemann

Poster

Abstract

On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER

David J. Jackson

Poster

Abstract

Time -to - understand treatment response

Wim Janssens

Poster

Abstract

Rates of clinical asthma remission in a severe eosinophilic asthma cohort on biologic treatment.

Feargal Helly

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}